Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Project description

Decreasing resistance to an important treatment for tuberculosis

Fields of science

• medical and health sciences › clinical medicine › pneumology › tuberculosis

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

• IMI2-2018-16-06 - Functional Ethionamide boosters: a novel combination for tuberculosis therapy

Call for proposal

H2020-JTI-IMI2-2018-16-single-stage

See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

BIOVERSYS AG

Net EU contribution

€ 6 813 875,00

Address

Hochbergerstrasse 60 C Technologiepark Basel
4057 Basel
Switzerland

Region

Schweiz/Suisse/Svizzera › Nordwestschweiz › Basel-Stadt

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 29 375,00

Participants (2)

Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

BioVersys SAS

France

Net EU contribution

€ 112 500,00

Address

Institut Pasteur De Lille U1177, 1 Rue Du Professeur Calmette
59000 Lille

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes

Region

Hauts-de-France › Nord-Pas de Calais › Nord

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 0,00

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

Spain

Net EU contribution

€ 0,00

Address

C/ Severo Ochoa Numero 2 Parque Tecnologico De Mad
28760 Tres Cantos Madrid

Region

Comunidad de Madrid › Comunidad de Madrid › Madrid

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 1 417 500,00